Shigeki Miyamoto
page-template,page-template-full_width,page-template-full_width-php,page,page-id-799,bridge-core-3.0.2,,vertical_menu_enabled,qode-title-hidden,qode_grid_1300,side_area_uncovered_from_content,qode-theme-ver-28.8,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.9.0,vc_responsive

Discovery Spotlight

Shigeki Miyamoto, PhD


Department of Oncology


NF-kB transcription factor mechanisms in physiology and disease


Our current research interest centers on investigating the signaling mechanisms and roles of the NF-κB transcription factor family in the DNA damage response and in the pathogenesis of multiple myeloma. We have over 25 years of research experiences in the NF-κB field and have contributed to this field by discovering two new NF-κB signaling pathways. The first involves a DNA damage induced NF-κB signaling pathway and the other relates to multiple myeloma drug resistance. We have generated new knock-in mouse models which are teaching us how DNA damage-induced NF-kB signaling modulates anti-cancer CD8 T cell immunity and how proper subcellular localization of the main inhibitor of NF-kB, IkBa, plays crucial roles in regulating functions of B and T lymphocytes and the development of lymphoid organs. We are also investigating the role of HAPLN1 as a new activator of NF-kB and STAT1 signaling and an inducer of drug resistance and dissemination of multiple myeloma. Our group employs a variety of approaches, including mouse models, human specimens, and biochemical, genomic, proteomic and bioengineering approaches, through collaboration with investigators with expertise in such areas.